marijuana stocks

Form 8-K for CANNAVEST CORP.


18-Aug-2015

Results of Operations and Financial Condition, Regulation FD Disclosure

Item 2.02 Results of Operations and Financial ConditionThe information provided below in “Item 7.01- Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

 

Item 7.01 Regulation FD DisclosureOn August 18, 2015, CannaVEST Corp. (the “Company”) announced the release of its Second Quarter 2015 earnings. A copy of the press release issued by the Company announcing the release of Second Quarter 2015 earnings is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

GrowGeneration Corp. (GRWG) Appoints Paul Rutenis as Chief Merchant Officer

GrowGeneration Appoints Paul Rutenis as Chief Merchant Officer GrowGeneration Corp. (NASDAQ: GRWG),…

4Front Ventures Corp. (FFNTF) to Report Second Quarter 2023 Financial Results on August 15, 2023

4Front Ventures to Report Second Quarter 2023 Financial Results on August 15,…

Rocky Mountain High Brands, Inc. (RMHB) Announces Production Run for Rocket High, California Lemonade

Rocky Mountain High Brands Announces Production Run for Rocket High, California Lemonade,…

Cara Therapeutics, Inc. (CARA) Reports Clinical Updates

Cara Therapeutics Reports Clinical Updates Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused…